Boehringer Ingelheim International GmbH and Medfield Diagnostics AB have signed a project agreement to “evaluate and test a novel mobile microwave based diagnosis technology for the detection of stroke in pre-hospital and hospital environments”.
Medfield will launch an international multicentre study to generate additional clinical evidence on the ability of the product Strokefinder MD100 to distinguish ischemic stroke from haemorrhagic stroke.
Under the agreement, Boehringer Ingelheim (BI) will co-finance this project. Medfield will retain full ownership of the study and make the results available to BI.
– We are both happy and proud that BI recognizes the potential with Strokefinder. This grant is a welcome contribution on our journey towards market acceptance for our product, says Dag Jungenfelt, CEO at Medfield.
The co-financing from BI is in the form of a 300 k€ grant.